$58.88
0.47 (-0.79%)
Last updated: Apr 16, 2026 00:42
Fundamentals Overview
Xenon Pharmaceuticals Inc. is near the high of its 52-week range with premium valuation, trading relatively flat today.
Valuation premium
Intrinsic value (DCF)
-95.9% downside vs price
Risk (Beta)
0.75 — lower vol
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
3M vs S&P 500: +42.1% · 3M vs Healthcare sector: +48.9%
Pressures (Sell):
DCF 95.9% downside vs price
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: C-. Current institutional positions: Buy: 14, Outperform: 9, Overweight: 7.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $2.44; current price is $58.88. That’s a -95.9% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | N/A |
| DCF value (model) | $2.44 (-95.9% vs price) |
| PEG (TTM) | N/A |
| P/B (TTM) | 8.02 |
| P/S (TTM) | 619.79 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 13.42 |
| Quick Ratio (TTM) | 13.42 |
| Cash Ratio (TTM) | 4.77 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | -46.12% |
| Gross margin (TTM) | -9.44% |
| Operating margin (TTM) | -49.74% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for XENE.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Wedbush | maintain | Outperform | Outperform | 2026-03-16 |
| Deutsche Bank | maintain | Buy | Buy | 2026-03-10 |
| Wells Fargo | maintain | Overweight | Overweight | 2026-03-10 |
| Wedbush | maintain | Outperform | Outperform | 2026-03-10 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-03-10 |
| Baird | maintain | Outperform | Outperform | 2026-03-09 |
| Needham | maintain | Buy | Buy | 2026-03-09 |
| Wells Fargo | maintain | Overweight | Overweight | 2026-02-27 |
| Needham | maintain | Buy | Buy | 2026-02-27 |
| JP Morgan | maintain | Overweight | Overweight | 2026-01-09 |
| Wells Fargo | maintain | Overweight | Overweight | 2025-12-11 |
| JP Morgan | maintain | Overweight | Overweight | 2025-11-18 |
| RBC Capital | maintain | Outperform | Outperform | 2025-11-04 |
| Needham | maintain | Buy | Buy | 2025-11-04 |
| Wells Fargo | maintain | Overweight | Overweight | 2025-11-04 |
| Chardan Capital | maintain | Buy | Buy | 2025-10-07 |
| RBC Capital | maintain | Outperform | Outperform | 2025-09-02 |
| RBC Capital | maintain | Outperform | Outperform | 2025-08-12 |
| Wedbush | maintain | Outperform | Outperform | 2025-08-12 |
| Chardan Capital | maintain | Buy | Buy | 2025-08-12 |
| RBC Capital | maintain | Outperform | Outperform | 2025-06-13 |
| Chardan Capital | maintain | Buy | Buy | 2025-05-13 |
| RBC Capital | maintain | Outperform | Outperform | 2025-05-13 |
| Needham | maintain | Buy | Buy | 2025-05-13 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-05-13 |
| Wells Fargo | maintain | Overweight | Overweight | 2025-05-13 |
| Goldman Sachs | maintain | Buy | Buy | 2025-04-17 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-02-24 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-12-12 |
| Needham | maintain | Buy | Buy | 2024-11-13 |